BioSpace News Archive

Monte Nido & Affiliates - the nation’s leading provider of eating disorder treatment for over two decades - announces the appointment of Melissa Orshan Spann, LMHC, PhD, CEDS-S as the company’s Chief Clinical Officer

The Columbus Organization, a leading provider of case management services for individuals with Intellectual and Developmental Disabilities, today announced that Johnny Callebs has been appointed as Executive State Director in Kentucky, overseeing case management services in the state

Xstrahl Medical, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and dermatological conditions, is spotlighting its RADiant treatment system at the 2019 CalDerm NorCal Conference at the Meritage, Napa Valley, CA.

Blueprint Medicines Corporation (NASDAQ: BPMC), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avapritinib for the treatment of adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Drug Enforcement Administration (DEA) has placed ZULRESSO™ (brexanolone) injection into Schedule IV of the Controlled Substances Act.

There are over 14,000 people on the national waiting list for a liver transplant, and around 20% will die before receiving a lifesaving transplant because of a lack of deceased donors.

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced receipt of a major research and development (R&D) grant from the German Federal Ministry of Education and Research (BMBF)’s “From Material to Innovation” program to lead a consortium investigating an anticoagulation-free hemodialysis (HD) option for end-stage renal disease (ESRD) patients

Morphic Therapeutic, a biotechnology company developing oral integrin therapies, today announced the appointment of former Gilead chief scientific officer and executive vice president of research and development, Norbert Bischofberger, Ph.D., to its Board of Directors.

Thermo-Rx® brand Senegalia Berlandieri Extract is a quantum leap in the field of weight loss backed by a clinical study -- one showed an increase in the metabolism by 22% in 45 minutes.

Welltower Inc. (NYSE: WELL) today released its annual corporate social responsibility (“CSR”) report.